NASDAQ:ATRA - Atara Biotherapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$51.05 +1.35 (+2.72 %)
(As of 05/25/2018 07:21 AM ET)
Previous Close$49.70
Today's Range$49.45 - $51.35
52-Week Range$11.80 - $54.45
Volume317,050 shs
Average Volume581,629 shs
Market Capitalization$2.18 billion
P/E Ratio-12.76
Dividend YieldN/A
Beta2.55

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics logoAtara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company was founded in 2012 and is headquartered in South San Francisco, California.

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930

Debt

Debt-to-Equity RatioN/A
Current Ratio19.66
Quick Ratio19.66

Price-To-Earnings

Trailing P/E Ratio-12.76
Forward P/E Ratio-12.57
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$9.99 per share
Price / Book5.11

Profitability

EPS (Most Recent Fiscal Year)($4.00)
Net Income$-119,490,000.00
Net MarginsN/A
Return on Equity-51.97%
Return on Assets-46.59%

Miscellaneous

Employees185
Outstanding Shares43,950,000

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.12. View Atara Biotherapeutics' Earnings History.

What price target have analysts set for ATRA?

9 brokerages have issued 12-month target prices for Atara Biotherapeutics' stock. Their predictions range from $18.00 to $70.00. On average, they anticipate Atara Biotherapeutics' stock price to reach $42.00 in the next year. View Analyst Ratings for Atara Biotherapeutics.

What are Wall Street analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (5/10/2018)
  • 2. Canaccord Genuity analysts commented, "We are updating details of our model and valuation table for ATRA, but our price target remains at $70 and our revenue estimates remain unchanged." (3/13/2018)

Who are some of Atara Biotherapeutics' key competitors?

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the folowing people:
  • Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 47)
  • Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 48)
  • Dr. Derrell D. Porter, Sr. VP & Global Commercial Head (Age 47)
  • Dr. Christopher M. Haqq, Exec. VP of R&D & Chief Scientific Officer (Age 52)
  • John Craighead, VP of Investor Relations & Corp. Communications

Has Atara Biotherapeutics been receiving favorable news coverage?

Media headlines about ATRA stock have trended somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a media sentiment score of 0.23 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 45.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (17.70%), Redmile Group LLC (9.64%), BlackRock Inc. (6.47%), Artal Group S.A. (2.84%), Neuberger Berman Group LLC (2.49%) and Federated Investors Inc. PA (1.08%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, John Mcgrath, Matthew K Fust and Mitchall G Clark. View Institutional Ownership Trends for Atara Biotherapeutics.

Which major investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including Old West Investment Management LLC and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, John Mcgrath, Matthew K Fust and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.

Which major investors are buying Atara Biotherapeutics stock?

ATRA stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Federated Investors Inc. PA, PointState Capital LP, Artal Group S.A., Northern Trust Corp, UBS Group AG and Pacific Heights Asset Management LLC. View Insider Buying and Selling for Atara Biotherapeutics.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $51.05.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $2.18 billion. The biotechnology company earns $-119,490,000.00 in net income (profit) each year or ($4.00) on an earnings per share basis. Atara Biotherapeutics employs 185 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.


MarketBeat Community Rating for Atara Biotherapeutics (ATRA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Atara Biotherapeutics (NASDAQ:ATRA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Atara Biotherapeutics in the last 12 months. Their average twelve-month price target is $42.00, suggesting that the stock has a possible downside of 17.73%. The high price target for ATRA is $70.00 and the low price target for ATRA is $18.00. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyHold
Consensus Rating Score: 2.442.442.502.40
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $42.00$42.00$34.50$26.75
Price Target Upside: 17.73% downside16.67% upside28.65% downside100.37% upside

Atara Biotherapeutics (NASDAQ:ATRA) Consensus Price Target History

Price Target History for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Canaccord GenuityReiterated RatingBuy$70.00MediumView Rating Details
4/10/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$56.00HighView Rating Details
4/6/2018William BlairReiterated RatingBuyMediumView Rating Details
3/15/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLowView Rating Details
3/5/2018Jefferies GroupBoost Price TargetBuy ➝ Buy$30.00 ➝ $46.00HighView Rating Details
2/28/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHighView Rating Details
2/15/2018CitigroupDowngradeNeutral ➝ SellHighView Rating Details
1/26/2018CowenInitiated CoverageOutperformHighView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$20.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Atara Biotherapeutics (NASDAQ:ATRA) Earnings History and Estimates Chart

Earnings by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) Earnings Estimates

2018 EPS Consensus Estimate: ($3.93)
2019 EPS Consensus Estimate: ($4.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.96)($0.85)($0.91)
Q2 20182($0.98)($0.97)($0.98)
Q3 20182($1.02)($0.98)($1.00)
Q4 20182($1.06)($1.03)($1.05)
Q1 20191($1.15)($1.15)($1.15)
Q2 20191($1.24)($1.24)($1.24)
Q3 20191($1.17)($1.17)($1.17)
Q4 20191($1.13)($1.13)($1.13)

Atara Biotherapeutics (NASDAQ ATRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.9230)($1.0470)ViewN/AView Earnings Details
2/27/2018Q4 2017($1.15)($1.15)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.97)($1.02)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.89)($0.94)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.77)($0.88)ViewN/AView Earnings Details
3/9/201712/31/2016($0.98)($0.63)ViewN/AView Earnings Details
11/4/2016Q3 2016($0.79)($0.88)ViewN/AView Earnings Details
8/8/2016Q2($0.61)($0.66)ViewN/AView Earnings Details
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details
3/3/2016Q4 2015($0.48)($0.75)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.53)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.42)($0.43)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.36)($0.42)ViewN/AView Earnings Details
2/26/2015Q4 2014($0.35)($0.67)ViewN/AView Earnings Details
11/12/2014Q314($4.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Atara Biotherapeutics (NASDAQ:ATRA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Atara Biotherapeutics (NASDAQ ATRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.60%
Insider Trading History for Atara Biotherapeutics (NASDAQ:ATRA)
Insider Trading History for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ ATRA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2018Isaac E CiechanoverCEOSell8,800$51.74$455,312.00812,613View SEC Filing  
5/18/2018Mitchall G ClarkEVPSell25,860$50.03$1,293,775.80107,972View SEC Filing  
5/16/2018Carol Giltner GallagherDirectorSell273$46.06$12,574.38111,465View SEC Filing  
5/16/2018Mitchall G ClarkEVPSell4,647$46.06$214,040.82357,905View SEC Filing  
5/15/2018Derrell PorterSVPSell16,334$45.02$735,356.6828,834View SEC Filing  
5/14/2018Matthew K FustDirectorSell12,286$43.57$535,301.0219,820View SEC Filing  
5/10/2018Isaac E CiechanoverCEOSell8,800$39.85$350,680.00812,613View SEC Filing  
5/8/2018Derrell PorterSVPSell1,544$40.15$61,991.6012,500View SEC Filing  
4/27/2018Isaac E CiechanoverCEOSell8,800$42.46$373,648.00View SEC Filing  
4/11/2018Isaac E CiechanoverCEOSell4,400$40.82$179,608.00812,613View SEC Filing  
3/29/2018Mitchall G ClarkEVPSell22,400$40.07$897,568.00View SEC Filing  
3/26/2018Christopher HaqqEVPSell18,327$39.79$729,231.33334,005View SEC Filing  
3/26/2018Isaac E CiechanoverCEOSell4,400$40.10$176,440.00206,478View SEC Filing  
3/20/2018John McgrathCFOSell6,000$40.41$242,460.0091,762View SEC Filing  
3/16/2018Isaac E CiechanoverCEOSell8,800$42.13$370,744.00812,613View SEC Filing  
3/12/2018Isaac E CiechanoverCEOSell1,000$46.31$46,310.00812,613View SEC Filing  
2/22/2018Isaac E CiechanoverCEOSell17,800$44.65$794,770.00812,613View SEC Filing  
2/20/2018Isaac E CiechanoverCEOSell8,700$45.28$393,936.00812,613View SEC Filing  
2/16/2018Carol Giltner GallagherDirectorSell1,183$46.50$55,009.50111,286View SEC Filing  
2/16/2018Isaac E CiechanoverCEOSell20,000$46.92$938,400.00812,613View SEC Filing  
2/16/2018John McgrathCFOSell13,000$47.07$611,910.0099,056View SEC Filing  
2/14/2018Isaac E CiechanoverCEOSell20,000$46.80$936,000.00808,675View SEC Filing  
2/9/2018Heather D TurnerEVPSell12,214$38.01$464,254.1477,112View SEC Filing  
2/9/2018Isaac E CiechanoverCEOSell8,800$37.44$329,472.00808,675View SEC Filing  
1/26/2018Isaac E CiechanoverCEOSell19,300$35.26$680,518.00743,675View SEC Filing  
1/24/2018Isaac E CiechanoverCEOSell48,500$34.58$1,677,130.00348,978View SEC Filing  
1/22/2018Isaac E CiechanoverCEOSell10,000$33.07$330,700.00348,978View SEC Filing  
1/16/2018Isaac E CiechanoverCEOSell600$30.38$18,228.00743,675View SEC Filing  
1/12/2018Isaac E CiechanoverCEOSell28,700$21.39$613,893.00743,675View SEC Filing  
1/12/2018John McgrathCFOSell37,000$24.35$900,950.0093,154View SEC Filing  
1/10/2018Isaac E CiechanoverCEOSell8,600$19.99$171,914.00743,675View SEC Filing  
12/29/2017Isaac E CiechanoverCEOSell22,200$18.29$406,038.00View SEC Filing  
12/29/2017John McgrathCFOSell32,000$20.00$640,000.00View SEC Filing  
12/29/2017John McgrathCFOSell32,000$20.00$640,000.0096,654View SEC Filing  
12/28/2017Isaac E CiechanoverCEOSell2,200$15.15$33,330.00743,675View SEC Filing  
12/13/2017Isaac E CiechanoverCEOSell4,400$14.65$64,460.00743,675View SEC Filing  
11/30/2017Isaac E CiechanoverCEOSell4,400$14.25$62,700.00View SEC Filing  
11/17/2017Gad SofferEVPSell7,000$15.00$105,000.00166,342View SEC Filing  
11/16/2017Carol Giltner GallagherDirectorSell1,184$14.20$16,812.80110,105View SEC Filing  
11/15/2017Christopher HaqqEVPSell1,604$13.36$21,429.44344,134View SEC Filing  
11/14/2017Isaac E CiechanoverCEOSell4,400$13.47$59,268.00737,767View SEC Filing  
10/27/2017Isaac E CiechanoverCEOSell4,400$13.59$59,796.00737,767View SEC Filing  
10/16/2017Christopher HaqqEVPSell6,000$14.35$86,100.00View SEC Filing  
10/12/2017Isaac E CiechanoverCEOSell4,400$15.02$66,088.00View SEC Filing  
10/11/2017Isaac E CiechanoverCEOSell2,200$15.25$33,550.00737,767View SEC Filing  
9/20/2017Isaac E CiechanoverCEOSell4,400$15.54$68,376.00737,767View SEC Filing  
9/15/2017Christopher HaqqEVPSell6,000$15.30$91,800.00349,305View SEC Filing  
9/7/2017Isaac E CiechanoverCEOSell4,400$15.02$66,088.00737,767View SEC Filing  
8/23/2017Isaac E CiechanoverCEOSell4,400$13.54$59,576.00737,767View SEC Filing  
8/16/2017Carol Giltner GallagherDirectorSell1,184$14.30$16,931.20108,922View SEC Filing  
8/16/2017John McgrathCFOSell4,200$14.31$60,102.00125,157View SEC Filing  
8/16/2017Mitchall G. ClarkEVPSell3,021$14.33$43,290.93View SEC Filing  
8/15/2017Christopher HaqqEVPSell7,604$14.75$112,159.00362,909View SEC Filing  
8/11/2017Isaac E CiechanoverCEOSell4,400$14.67$64,548.00731,859View SEC Filing  
7/25/2017Isaac E CiechanoverCEOSell5,500$16.49$90,695.00731,859View SEC Filing  
7/24/2017Isaac E CiechanoverCEOSell2,800$16.94$47,432.00731,859View SEC Filing  
7/17/2017Christopher HaqqEVPSell6,000$14.92$89,520.00362,080View SEC Filing  
6/15/2017Christopher HaqqEVPSell6,000$12.65$75,900.00368,080View SEC Filing  
6/9/2017Carol Giltner GallagherDirectorSell1,000$13.15$13,150.00108,374View SEC Filing  
5/31/2017Isaac E CiechanoverCEOSell6,900$13.35$92,115.00731,859View SEC Filing  
5/30/2017Isaac E CiechanoverCEOSell3,450$13.44$46,368.00731,859View SEC Filing  
5/18/2017Isaac E CiechanoverCEOSell4,800$14.91$71,568.00731,859View SEC Filing  
5/16/2017Carol Giltner GallagherDirectorSell1,184$15.25$18,056.00103,741View SEC Filing  
5/16/2017Gad SofferEVPSell12,674$15.16$192,137.84259,527View SEC Filing  
5/16/2017John McgrathCFOSell4,000$15.11$60,440.00113,762View SEC Filing  
4/26/2017Isaac E CiechanoverCEOSell7,200$17.56$126,432.00725,951View SEC Filing  
4/25/2017Isaac E CiechanoverCEOSell3,600$17.33$62,388.00725,951View SEC Filing  
4/17/2017Christopher HaqqEVPSell6,000$17.28$103,680.00380,855View SEC Filing  
4/11/2017Isaac E CiechanoverCEOSell7,200$17.03$122,616.00725,951View SEC Filing  
3/28/2017Isaac E CiechanoverCEOSell16,000$20.06$320,960.00725,951View SEC Filing  
3/23/2017John McgrathCFOSell14,000$20.65$289,100.00119,327View SEC Filing  
3/17/2017Isaac E CiechanoverCEOSell30,800$19.38$596,904.00725,951View SEC Filing  
3/10/2017Gad SofferEVPSell2,500$20.00$50,000.00266,527View SEC Filing  
3/10/2017John McgrathCFOSell24,000$20.00$480,000.00126,827View SEC Filing  
2/21/2017John McgrathCFOSell9,000$15.14$136,260.00150,827View SEC Filing  
2/16/2017Carol Giltner GallagherDirectorSell1,183$16.10$19,046.30102,558View SEC Filing  
2/16/2017Isaac E CiechanoverCEOSell4,800$15.56$74,688.00725,951View SEC Filing  
2/16/2017Mitchall G. ClarkEVPSell3,059$15.96$48,821.64View SEC Filing  
2/15/2017Christopher HaqqEVPSell7,604$15.49$117,785.96400,459View SEC Filing  
2/10/2017Gad SofferEVPSell6,274$15.47$97,058.78269,938View SEC Filing  
2/9/2017Christopher HaqqEVPSell13,975$15.46$216,053.50399,630View SEC Filing  
2/3/2017Isaac E CiechanoverCEOSell4,800$13.66$65,568.00555,044View SEC Filing  
1/18/2017Isaac E CiechanoverCEOSell6,000$14.24$85,440.00555,044View SEC Filing  
1/17/2017Christopher HaqqEVPSell6,000$14.27$85,620.00364,105View SEC Filing  
1/6/2017Isaac E CiechanoverCEOSell8,400$16.89$141,876.00555,044View SEC Filing  
12/23/2016Isaac E CiechanoverCEOSell4,800$15.22$73,056.00555,044View SEC Filing  
12/15/2016Christopher HaqqInsiderSell6,000$15.40$92,400.00370,105View SEC Filing  
12/7/2016Isaac E CiechanoverCEOSell7,200$17.93$129,096.00555,044View SEC Filing  
11/23/2016Isaac E CiechanoverCEOSell12,000$18.34$220,080.00555,044View SEC Filing  
11/22/2016Isaac E CiechanoverCEOSell8,400$18.21$152,964.00555,044View SEC Filing  
11/16/2016Carol Giltner GallagherDirectorSell1,184$19.35$22,910.4099,377View SEC Filing  
11/16/2016Gad SofferCOOSell16,718$20.00$334,360.00225,667View SEC Filing  
11/16/2016Mitchall G ClarkInsiderSell2,995$19.53$58,492.3598,182View SEC Filing  
11/14/2016Gad SofferCOOSell9,582$20.55$196,910.10225,667View SEC Filing  
11/11/2016John McgrathCFOSell5,000$19.84$99,200.0091,823View SEC Filing  
10/27/2016Isaac E CiechanoverCEOSell4,800$13.81$66,288.00549,136View SEC Filing  
10/14/2016Isaac E CiechanoverCEOSell4,800$15.96$76,608.00549,136View SEC Filing  
10/12/2016John McgrathCFOSell5,000$17.47$87,350.0096,823View SEC Filing  
9/28/2016Isaac E CiechanoverCEOSell12,000$20.87$250,440.00406,578View SEC Filing  
9/16/2016Isaac E CiechanoverCEOSell7,200$19.36$139,392.00229,136View SEC Filing  
8/23/2016Isaac E CiechanoverCEOSell9,600$22.33$214,368.00229,136View SEC Filing  
8/16/2016Gad SofferCOOSell5,356$22.41$120,027.96146,460View SEC Filing  
8/15/2016Christopher HaqqInsiderSell1,346$22.32$30,042.72295,294View SEC Filing  
7/21/2016Isaac E CiechanoverCEOSell9,600$22.11$212,256.00223,228View SEC Filing  
7/8/2016Isaac E CiechanoverCEOSell9,600$22.88$219,648.00223,228View SEC Filing  
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00223,228View SEC Filing  
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00223,228View SEC Filing  
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00223,228View SEC Filing  
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00223,228View SEC Filing  
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.6495,829View SEC Filing  
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57138,125View SEC Filing  
5/16/2016John McgrathCFOSell5,395$15.77$85,079.1586,519View SEC Filing  
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.9587,912View SEC Filing  
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00217,321View SEC Filing  
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00217,321View SEC Filing  
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70217,321View SEC Filing  
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.005,500View SEC Filing  
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.9094,280View SEC Filing  
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47128,510View SEC Filing  
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.0047,440View SEC Filing  
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.0047,440View SEC Filing  
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.002,500View SEC Filing  
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.0047,440View SEC Filing  
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.0047,440View SEC Filing  
11/30/2015John McgrathCFOSell6,000$40.00$240,000.0036,356View SEC Filing  
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.0047,440View SEC Filing  
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.4093,098View SEC Filing  
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.9272,013View SEC Filing  
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.0041,532View SEC Filing  
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.0041,532View SEC Filing  
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.0041,532View SEC Filing  
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.0041,532View SEC Filing  
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00240,890View SEC Filing  
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.0041,532View SEC Filing  
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.4891,916View SEC Filing  
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Atara Biotherapeutics (NASDAQ ATRA) News Headlines

Source:
DateHeadline
Atara Biotherapeutics (ATRA) CEO Sells $455,312.00 in StockAtara Biotherapeutics (ATRA) CEO Sells $455,312.00 in Stock
www.americanbankingnews.com - May 22 at 7:28 PM
Insider Selling: Atara Biotherapeutics (ATRA) EVP Sells 25,860 Shares of StockInsider Selling: Atara Biotherapeutics (ATRA) EVP Sells 25,860 Shares of Stock
www.americanbankingnews.com - May 21 at 7:17 PM
Atara Biotherapeutics: What Q1 2018 Earnings Foretell?Atara Biotherapeutics: What Q1 2018 Earnings Foretell?
seekingalpha.com - May 18 at 9:21 AM
Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus ...Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus ...
globenewswire.com - May 17 at 5:38 PM
Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology AssociationAtara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association
finance.yahoo.com - May 17 at 5:38 PM
Atara Biotherapeutics (ATRA) Given Consensus Rating of "Buy" by BrokeragesAtara Biotherapeutics (ATRA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 17 at 1:51 PM
Atara Biotherapeutics: A Gift That Keeps On GivingAtara Biotherapeutics: A Gift That Keeps On Giving
seekingalpha.com - May 17 at 8:56 AM
Insider Selling: Atara Biotherapeutics (ATRA) EVP Sells 4,647 Shares of StockInsider Selling: Atara Biotherapeutics (ATRA) EVP Sells 4,647 Shares of Stock
www.americanbankingnews.com - May 16 at 10:29 PM
Insider Selling: Atara Biotherapeutics (ATRA) Director Sells 273 Shares of StockInsider Selling: Atara Biotherapeutics (ATRA) Director Sells 273 Shares of Stock
www.americanbankingnews.com - May 16 at 10:28 PM
Atara Biotherapeutics (ATRA) Director Matthew K. Fust Sells 12,286 SharesAtara Biotherapeutics (ATRA) Director Matthew K. Fust Sells 12,286 Shares
www.americanbankingnews.com - May 16 at 10:16 PM
Atara Biotherapeutics (ATRA) SVP Derrell Porter Sells 16,334 SharesAtara Biotherapeutics (ATRA) SVP Derrell Porter Sells 16,334 Shares
www.americanbankingnews.com - May 16 at 10:15 PM
Q2 2018 Earnings Estimate for Atara Biotherapeutics Issued By Jefferies Group (ATRA)Q2 2018 Earnings Estimate for Atara Biotherapeutics Issued By Jefferies Group (ATRA)
www.americanbankingnews.com - May 14 at 2:48 AM
Atara Biotherapeutics: What The Q1 2018 Earnings Foretell?Atara Biotherapeutics: What The Q1 2018 Earnings Foretell?
seekingalpha.com - May 13 at 9:02 AM
Rounds Report: Omeros Rallied While Stellar FDA Due Diligence To Help Atara BiotherapeuticsRounds Report: Omeros Rallied While Stellar FDA Due Diligence To Help Atara Biotherapeutics
seekingalpha.com - May 13 at 9:02 AM
Rounds Report: Omeros Rallied While The Stellar FDA Due Diligence To Help AtaraRounds Report: Omeros Rallied While The Stellar FDA Due Diligence To Help Atara
seekingalpha.com - May 12 at 9:10 AM
Atara Biotherapeutics (ATRA) CEO Sells $350,680.00 in StockAtara Biotherapeutics (ATRA) CEO Sells $350,680.00 in Stock
www.americanbankingnews.com - May 10 at 10:15 PM
Zacks: Analysts Expect Atara Biotherapeutics (ATRA) to Post -$0.89 EPSZacks: Analysts Expect Atara Biotherapeutics (ATRA) to Post -$0.89 EPS
www.americanbankingnews.com - May 10 at 9:23 PM
Atara Biotherapeutics (ATRA) Issues  Earnings ResultsAtara Biotherapeutics (ATRA) Issues Earnings Results
www.americanbankingnews.com - May 10 at 6:12 PM
Zacks Investment Research Lowers Atara Biotherapeutics (ATRA) to SellZacks Investment Research Lowers Atara Biotherapeutics (ATRA) to Sell
www.americanbankingnews.com - May 10 at 5:36 PM
Q2 2018 EPS Estimates for Atara Biotherapeutics (ATRA) Reduced by AnalystQ2 2018 EPS Estimates for Atara Biotherapeutics (ATRA) Reduced by Analyst
www.americanbankingnews.com - May 10 at 7:26 AM
Form 4 Atara Biotherapeutics, For: May 08 Filed by: Porter DerrellForm 4 Atara Biotherapeutics, For: May 08 Filed by: Porter Derrell
www.streetinsider.com - May 9 at 8:50 AM
BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy CollaborationBRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration
www.reuters.com - May 9 at 8:50 AM
BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05
www.reuters.com - May 9 at 8:50 AM
Biotech Industry Veteran Dietmar Berger, MD, Ph.D., Joins Atara Biotherapeutics as Global Head of Research and ...Biotech Industry Veteran Dietmar Berger, MD, Ph.D., Joins Atara Biotherapeutics as Global Head of Research and ...
globenewswire.com - May 9 at 8:50 AM
Atara Biotherapeutics (ATRA) SVP Sells $61,991.60 in StockAtara Biotherapeutics (ATRA) SVP Sells $61,991.60 in Stock
www.americanbankingnews.com - May 8 at 10:28 PM
Atara Biotherapeutics (ATRA) Earns "Buy" Rating from Canaccord GenuityAtara Biotherapeutics (ATRA) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - May 8 at 9:15 PM
Atara Biotherapeutics: 1Q Earnings SnapshotAtara Biotherapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:46 AM
Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and DevelopmentBiotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development
finance.yahoo.com - May 7 at 8:44 AM
Atara Biotherapeutics (ATRA) Upgraded by ValuEngine to "Strong-Buy"Atara Biotherapeutics (ATRA) Upgraded by ValuEngine to "Strong-Buy"
www.americanbankingnews.com - May 4 at 12:21 AM
Atara Biotherapeutics (ATRA) Rating Increased to Buy at Zacks Investment ResearchAtara Biotherapeutics (ATRA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 1 at 7:10 PM
Isaac E. Ciechanover Sells 8,800 Shares of Atara Biotherapeutics (ATRA) StockIsaac E. Ciechanover Sells 8,800 Shares of Atara Biotherapeutics (ATRA) Stock
www.americanbankingnews.com - April 30 at 7:44 PM
Atara Biotherapeutics (ATRA) Upgraded to "Buy" by BidaskClubAtara Biotherapeutics (ATRA) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - April 26 at 1:31 PM
-$0.93 Earnings Per Share Expected for Atara Biotherapeutics (ATRA) This Quarter-$0.93 Earnings Per Share Expected for Atara Biotherapeutics (ATRA) This Quarter
www.americanbankingnews.com - April 23 at 11:18 AM
Atara Biotherapeutics (ATRA) Receives Average Recommendation of "Hold" from BrokeragesAtara Biotherapeutics (ATRA) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 22 at 1:36 PM
3 Growth Stocks for Successful Investors3 Growth Stocks for Successful Investors
finance.yahoo.com - April 21 at 4:58 PM
Reader Inquiry: Whats The Outlook For Atara Biotherapeutics After The Recent Secondary?Reader Inquiry: What's The Outlook For Atara Biotherapeutics After The Recent Secondary?
seekingalpha.com - April 20 at 8:53 AM
Atara Biotherapeutics (ATRA) Downgraded to Strong Sell at ValuEngineAtara Biotherapeutics (ATRA) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - April 14 at 2:30 PM
Insider Selling: Atara Biotherapeutics (ATRA) CEO Sells 4,400 Shares of StockInsider Selling: Atara Biotherapeutics (ATRA) CEO Sells 4,400 Shares of Stock
www.americanbankingnews.com - April 12 at 7:37 PM
Atara Biotherapeutics (ATRA) Earns Overweight Rating from Analysts at JPMorgan ChaseAtara Biotherapeutics (ATRA) Earns Overweight Rating from Analysts at JPMorgan Chase
www.americanbankingnews.com - April 10 at 8:39 AM
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - April 9 at 4:59 PM
-$0.91 EPS Expected for Atara Biotherapeutics (ATRA) This Quarter-$0.91 EPS Expected for Atara Biotherapeutics (ATRA) This Quarter
www.americanbankingnews.com - April 6 at 1:14 PM
Atara Biotherapeutics (ATRA) Receives "Buy" Rating from William BlairAtara Biotherapeutics (ATRA) Receives "Buy" Rating from William Blair
www.americanbankingnews.com - April 6 at 11:31 AM
Atara Biotherapeutics (ATRA) Downgraded to "Hold" at BidaskClubAtara Biotherapeutics (ATRA) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 5 at 2:08 PM
Atara Biotherapeutics Forecasted to Post Q1 2019 Earnings of ($1.06) Per Share (ATRA)Atara Biotherapeutics Forecasted to Post Q1 2019 Earnings of ($1.06) Per Share (ATRA)
www.americanbankingnews.com - April 4 at 7:58 AM
Atara Biotherapeutics (ATRA) EVP Mitchall G. Clark Sells 22,400 SharesAtara Biotherapeutics (ATRA) EVP Mitchall G. Clark Sells 22,400 Shares
www.americanbankingnews.com - April 3 at 10:10 PM
Atara Biotherapeutics (ATRA) Upgraded to "Buy" by ValuEngineAtara Biotherapeutics (ATRA) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - April 3 at 6:58 PM
Atara Biotherapeutics (ATRA) Upgraded at CitigroupAtara Biotherapeutics (ATRA) Upgraded at Citigroup
www.americanbankingnews.com - March 31 at 12:12 AM
Form 4 Atara Biotherapeutics, For: Mar 26 Filed by: Ciechanover Isaac E.Form 4 Atara Biotherapeutics, For: Mar 26 Filed by: Ciechanover Isaac E.
www.streetinsider.com - March 29 at 8:58 AM
Atara Biotherapeutics (ATRA) Upgraded by BidaskClub to "Buy"Atara Biotherapeutics (ATRA) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - March 28 at 9:48 PM
Atara Biotherapeutics Inc (ATRA) Receives Average Rating of "Hold" from AnalystsAtara Biotherapeutics Inc (ATRA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 28 at 1:10 PM

SEC Filings

Atara Biotherapeutics (NASDAQ:ATRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Atara Biotherapeutics (NASDAQ:ATRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Atara Biotherapeutics (NASDAQ ATRA) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.